Literature DB >> 16599595

A new class of glucosidase inhibitor: analogues of the naturally occurring glucosidase inhibitor salacinol with different ring heteroatom substituents and acyclic chain extension.

Hui Liu1, Lyann Sim, David R Rose, B Mario Pinto.   

Abstract

Six chain-extended analogues of the naturally occurring glycosidase inhibitor salacinol, with ring-heteroatom variation, were synthesized for structure-activity studies with different glycosidase enzymes. The syntheses involved the reaction of PMB-protected D- and L- seleno-, thio-, and iminoarabinitol with a benzylidene- and isopropylidene-protected 1,3-cyclic sulfate, derived from commercially available D-sorbitol, in 1,1,1,3,3,3-hexafluoro-2-propanol containing potassium carbonate. Deprotection of the products afforded the novel selenonium, sulfonium, and iminium analogues of salacinol containing polyhydroxylated, monosulfated, extended acyclic chains of 6-carbons, differing in stereochemistry at the stereogenic centers and ring-heteroatom constitution. Four of these compounds inhibit recombinant human maltase glucoamylase, one of the key intestinal enzymes involved in the breakdown of glucose oligosaccharides in the small intestine, with Ki values in the micromolar range, thus providing lead candidates for the treatment of Type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16599595     DOI: 10.1021/jo052539r

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  2 in total

1.  Synthesis of 4-alkylaminoimidazo[1,2-a]pyridines linked to carbamate moiety as potent α-glucosidase inhibitors.

Authors:  Mina Saeedi; Maryam Raeisi-Nafchi; Sepideh Sobhani; Seyedeh Sara Mirfazli; Mahsa Zardkanlou; Somayeh Mojtabavi; Mohammad Ali Faramarzi; Tahmineh Akbarzadeh
Journal:  Mol Divers       Date:  2020-10-12       Impact factor: 2.943

Review 2.  Herbal tea, a novel adjuvant therapy for treating type 2 diabetes mellitus: A review.

Authors:  Xiangyuan Zhang; Lili Zhang; Boxun Zhang; Ke Liu; Jun Sun; Qingwei Li; Linhua Zhao
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.